Other · developed by ASTRAZENECA
AZD6489 is an agent given as a single intramuscular injection. It is being studied in respiratory syncytial virus (RSV) infection.
Summary written with AI from the sources listed at the end of this page.
RSV Respiratory Syncytial Virus
Updated Nov 1, 2026. Something wrong or missing? Report it on the AZN page.
See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AZN catalysts and pipeline →